Diabetes, Vol 29, Issue 1 41-49, Copyright © 1980 by American Diabetes Association

ARTICLES

Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation

G Sartor, B Schersten, S Carlstrom, A Melander, A Norden and G Persson

In a diabetes detection survey carried out between 1962 and 1965, 2477 (1.1%) of 228,883 subjects had Clinistix-positive glucosuria after a carbohydrate-rich luncheon meal. Of these 2477, 578 displayed impaired tolerance to oral glucose without having manifest diabetes. From this group, 267 men were divided into five groups and subjected to the following treatments and controls: (a) diet regulation and 0.5 g tolbutamide t.i.d. (N = 49), annual oral glucose tolerance test (OGTT); (b) diet regulation and one placebo tablet t.i.d. (N = 48), annual OGTT; (c) diet regulation only (N = 50), annual OGTT; (d) no treatment (N = 61), annual OGTT; and (e) no treatment, OGTT at follow-up (N = 59 at follow-up). In addition, a control group was included comprised of men with normal OGTT (N = 52). At follow-up, 29% of those without diet regulation and medication (group e: N = 59) had developed diabetes. Of those on diet regulation, but without active medication (group b plus group c, N = 98), 13% had diabetes. No individual maintaining tolbutamide and diet regulation (N = 23) had progressed to diabetes. In this group, 80% of those later examined (N = 11) had serum tolbutamide concentrations in the therapeutic range. No individual with initially normal OGTT developed diabetes or impaired OGTT. The findings suggest that normal oral glucose tolerance signifies little risk of progress to impaired glucose tolerance and manifest diabetes, whereas impaired glucose tolerance is associated with a high risk of progression to diabetes. In addition, it seems possible that treatment with diet regulation, in combination with tolbutamide, may prevent or postpone progression from impaired glucose tolerance to manifest diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Bianchi, R. Miccoli, G. Penno, and S. Del Prato Primary Prevention of Cardiovascular Disease in People With Dysglycemia Diabetes Care, February 1, 2008; 31(Supplement_2): S208 - S214. [Abstract] [Full Text] [PDF]

				R. E Pratley and G. Matfin Review: Pre-diabetes: clinical relevance and therapeutic approach The British Journal of Diabetes & Vascular Disease, May 1, 2007; 7(3): 120 - 129. [Abstract] [PDF]

				Z. T. Bloomgarden Second World Congress on the Insulin Resistance Syndrome: Hypertension, cardiovascular disease, and treatment approaches Diabetes Care, August 1, 2005; 28(8): 2073 - 2080. [Full Text] [PDF]

				J Oldroyd, M Banerjee, A Heald, and K Cruickshank Diabetes and ethnic minorities Postgrad. Med. J., August 1, 2005; 81(958): 486 - 490. [Abstract] [Full Text] [PDF]

				A. H Frid, M. Nilsson, J. J. Holst, and I. M. Bjorck Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects Am. J. Clinical Nutrition, July 1, 2005; 82(1): 69 - 75. [Abstract] [Full Text] [PDF]

				S. Del Prato, R. Miccoli, and G. Penno Review: The importance of effective early phase insulin secretion The British Journal of Diabetes & Vascular Disease, July 1, 2005; 5(4): 198 - 202. [Abstract] [PDF]

				D A Stakos, D P Schuster, E A Sparks, C F Wooley, K Osei, and H Boudoulas Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: double blind, prospective, randomised study Heart, May 1, 2005; 91(5): 589 - 594. [Abstract] [Full Text] [PDF]

				R. Padwal, S. R. Majumdar, J. A. Johnson, J. Varney, and F. A. McAlister A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes Diabetes Care, March 1, 2005; 28(3): 736 - 744. [Abstract] [Full Text] [PDF]

				G. Davey Smith, Y. Bracha, K. H. Svendsen, J. D. Neaton, S. M. Haffner, L. H. Kuller, and for the Multiple Risk Factor Intervention Trial Re Incidence of Type 2 Diabetes in the Randomized Multiple Risk Factor Intervention Trial Ann Intern Med, March 1, 2005; 142(5): 313 - 322. [Abstract] [Full Text] [PDF]

				E. Bonora, S. Kiechl, J. Willeit, F. Oberhollenzer, G. Egger, J. B. Meigs, R. C. Bonadonna, and M. Muggeo Population-Based Incidence Rates and Risk Factors for Type 2 Diabetes in White Individuals: The Bruneck Study Diabetes, July 1, 2004; 53(7): 1782 - 1789. [Abstract] [Full Text] [PDF]

				Centers for Disease Control and Prevention Primary Primary Prevention of Type 2 Diabetes Mellitus by Lifestyle Intervention: Implications for Health Policy Ann Intern Med, June 1, 2004; 140(11): 951 - 957. [Abstract] [Full Text] [PDF]

				L. M. Prisant Preventing Type II Diabetes Mellitus J. Clin. Pharmacol., April 1, 2004; 44(4): 406 - 413. [Abstract] [Full Text] [PDF]

				R. A Defronzo Impaired glucose tolerance: do pharmacological therapies correct the underlying metabolic disturbance? The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1_suppl): S24 - S40. [Abstract] [PDF]

				C. Saloranta, C. Guitard, E. Pecher, P. de Pablos-Velasco, K. Lahti, P. Brunel, and L. Groop Nateglinide Improves Early Insulin Secretion and Controls Postprandial Glucose Excursions in a Prediabetic Population Diabetes Care, December 1, 2002; 25(12): 2141 - 2146. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden European Association for the Study of Diabetes (EASD) 2001 Meeting Diabetes Care, July 1, 2002; 25(7): 1229 - 1236. [Full Text] [PDF]

				L. S. Hermann and N. Wiernsperger Impaired glucose tolerance and metformin: clinical and mechanistic aspects The British Journal of Diabetes & Vascular Disease, May 1, 2002; 2(3): 177 - 183. [Abstract] [PDF]

				S. H. Saydah, C. M. Loria, M. S. Eberhardt, and F. L. Brancati Subclinical States of Glucose Intolerance and Risk of Death in the U.S. Diabetes Care, March 1, 2001; 24(3): 447 - 453. [Abstract] [Full Text]

				T. W. Gress, F. J. Nieto, E. Shahar, M. R. Wofford, F. L. Brancati, and The Atherosclerosis Risk in Communities Study Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus N. Engl. J. Med., March 30, 2000; 342(13): 905 - 912. [Abstract] [Full Text] [PDF]

				A Klamann, P Sarfert, V Launhardt, G Schulte, W.H Schmiegel, and M.A Nauck Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide) Eur. Heart J., February 1, 2000; 21(3): 220 - 229. [Abstract] [PDF]

				J. Levy, R. Morris, M. Hammersley, and R. Turner Discrimination, adjusted correlation, and equivalence of imprecise tests: application to glucose tolerance Am J Physiol Endocrinol Metab, February 1, 1999; 276(2): E365 - E375. [Abstract] [Full Text] [PDF]